NNGH is a cell-permeable, broad-spectrum inhibitor of matrix metalloproteinases (MMPs). It blocks the activity of MMP-8, -9, -12, -13, and -20 with Ki values of 9, 2.6, 4.3, 3.1, and 17 nM, respectively. It also inhibits MMP-1, -3, -7, and -10 with Ki values of 0.17, 0.13, 13, and 0.1 μM, respectively. It is commonly used to study the role of MMP-3 (stromelysin 1) in biological systems.
MMP-3 Inhibitor II is a cell-permeable, broad-spectrum inhibitor of matrix metalloproteinases (MMPs). It blocks the activity of MMP-8, -9, -12, -13, and -20 with Ki values of 9, 2.6, 4.3, 3.1, and 17 nM, respectively. It also inhibits MMP-1, -3, -7, and -10 with Ki values of 0.17, 0.13, 13, and 0.1 μM, respectively. It is commonly used to study the role of MMP-3 (stromelysin 1) in biological systems.[Cayman Chemical]
NNGH acts as a matrix metalloproteinase (MMP) inhibitor affecting the degredation of all the components of the extracellular matrix. Thought to be crucial for agressive processes tumor metastasis and angiogenesis.
Contains 5 mg each of MMP-2/MMP-9 Inhibitor I (Cat. No.
444241) and MMP-3 Inhibitor II (Cat. No.
444225), and 1 mg each of GM 6001 (Cat. No.
364205), GM 6001, Negative Control (Cat. No.
364210), and MMP-8 Inhibitor I (Cat. No.
444237).
previous study found that nngh was one of the most prominent representatives of a family of nanomolar inhibitors for some mmps. in addition, the x-ray structure of the nngh-mmp-12 complex showed that the interaction of nngh with the active site of the enzyme involved the binding of the hydroxamic functional group to the catalytic zn ion and the binding of the aromatic group to the s1 subsite [1].
previous animal study found that the repeated administration of nngh to wt mice was able to block the mmp-3 levels, which could reduce the number of adherent retinal leukocytes by 60% as compared to vehicle-treated mice. in addition, the administration of nngh could even lead to a more pronounced decrease in leukocyte adhesion and the treatment of mmp-3-/- mice with nngh showed a reduced hypothermic response as compared to vehicle-injected mmp-3-/- mice [2].
1) MacPherson et al. (1997), Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits; J. Med. Chem., 40 2525
2) Jeng et al. (1998), Sulfonamide-based hydroxamic acids as potent inhibitors of mouse macrophage metalloelastase; Bioorg. Med. Chem. Lett., 8 897
3) Christianson et al. (2012), Spinal matrix metalloproteinase 3 mediates inflammatory hyperalgesia via a tumor necrosis factor-dependent mechanism; J. Neuroscience, 200 199